Introduction {#s1}
============

Traditional Chinese medicine, characterized by a holistic approach, has attracted increasing attention worldwide because of its satisfactory clinical efficacy ([@B15]; [@B66]; [@B6]). Chinese herbal medicine, as the mainstay and principal form of traditional Chinese medicine practice, is composed of multiple herbal ingredients and hundreds of chemical compounds ([@B70]). Hence, it is difficult to fully understand their effective ingredients and the mechanism of action which depends on the overall interactions among all the ingredients.

Qiliqiangxin capsule (QLQX), comprising 11 crude herbs, has been clinically used for treating chronic heart failure (CHF) in China, providing an effective alternative for treatments of CHF ([@B31]; [@B53]; [@B49]). Chemically, flavonoids, saponins, cardiac glycosides, diterpene quinones, phenolic acids, diterpene alkaloids, and triterpenoids have been identified as the main constituents of QLQX ([@B63]). Recent pharmacological studies showed that QLQX performs various activities, including attenuating atrial structural remodeling ([@B55]), improving endothelial cell function ([@B7]), and protecting cardiac myocytes and mitochondrial function ([@B65]). However, the active compounds, potential targets, and pathways involved in these effects have not been systematically investigated.

Recently, integrated strategies based on bioinformatics, system biology, and high-throughput analytical techniques have emerged as a holistic and efficient tool to solve this issue ([@B39]; [@B59]; [@B25]). Network pharmacology gives us helpful tools to screen potential bioactive ingredients and understand the molecular mechanisms underlying the therapeutic effects by constructing component--target and target--disease networks ([@B30]; [@B62]). In recent years, the network pharmacology-based method has been used to analyze the system-level mechanisms of mono- and poly-pharmacology, manifesting "multicompound, multitarget" characteristics ([@B13]; [@B41]). However, there exist limitations in the insufficient accumulation and poor quality of traditional Chinese medicine-related data, and the nonreproducible nature of the existing data ([@B68]). The information on the active constituents of Chinese herbal medicine is critical for accurate assessments of the network. Thus, the greater the reliability and correlation of the information on the active constituents, the more convincing will be the results of network research. It has also been accepted that the components absorbed into the blood that attain a certain blood concentration can produce pharmacodynamics effects and are considered pharmacologically active substances ([@B32]; [@B35]). Therefore, pharmacokinetics study provides powerful evidence for determining the main active compounds absorbed into the blood and deciphering their process *in vivo*.

In the current study, a comprehensive method focusing on the main active compounds was used to illustrate the molecular mechanisms of QLQX by adopting pharmacokinetics study, network pharmacological analysis, and experimental validation. The flowchart is illustrated in [**Figure 1**](#f1){ref-type="fig"}. Briefly, (1) a pharmacokinetics study was employed to determine the main active components of QLQX; (2) a component--target (C--T) network was established to visualize the synergistic interactions between the targets of the main active components and CHF; (3) topological parameters of the C--T network, clustering, and pathway enrichment analysis of major hubs of QLQX against CHF were used to pinpoint the hub targets and pathways; (4) the hub targets determined by topological parameters and clustering analysis were used to construct the protein--protein interaction (PPI) network; (5) some hub targets in the PPI network were experimentally validated in the human cardiac microvascular endothelial cell (HCMEC).

![Flowchart of the study.](fphar-10-01046-g001){#f1}

Materials and Methods {#s2}
=====================

Reagents and Materials {#s2_1}
----------------------

The powder of QLQX was provided by Yiling Pharmaceutical Co. Ltd. (Shijiazhuang, China). Astragaloside, calycosin-7-glucoside, sinapine bisulfate, ginsenoside Rb1, Rb~2~, Rg~1~, Rg~3~, Rd, Re, Rf, and F~2~, salvianolic acid A, salvianolic acid B, danshensu, rosmarinic acid, protocatechuic acid, hydroxysafflor yellow A, formononetin, hesperidin, rutin, quercetin, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine, and benzoylhypaconine were obtained from the National Institutes for Food and Drug Control (Beijing, China), and ginsenoside Rc, lithospermic acid, and aconitine were obtained from Shanghai Yuanye Biotechnology Co. Ltd. (Shanghai, China). High-performance liquid chromatography (HPLC)-grade methanol, acetonitrile, and ammonium acetate were obtained from Fisher Scientific International Inc. (Fair Lawn, NJ), and formic acid was obtained from CNW Technologies GmbH (Duesseldorf, Germany). HCMEC and complete growth medium \[containing 90% high Dulbecco's modified Eagle medium (H-DMEM), 10% fetal bovine serum (FBS), and penicillin/streptomycin\] were purchased from BeNa Culture Collection (Beijing, China). Methylthiazolyldiphenyl-tetrazolium bromide (MTT) and bicinchoninic acid assay (BCA) protein assay kit were obtained from Beyotime (Shanghai, China). Rabbit antihuman monoclonal antibodies (*JAK2*, *phosphorylated-JAK2*, *STAT3*, *phosphorylated-STAT3*, *VEGFA*, and *β-actin*) and mouse antihuman monoclonal antibodies (*IL-6*) were provided by Beyotime (Shanghai, China). Rabbit antihuman monoclonal antibodies (*ADRB1*, *ADRB2*) were provided by Guidechem (Hangzhou, China).

HPLC-MS/MS Method for Pharmacokinetics Study {#s2_2}
--------------------------------------------

High-performance liquid chromatography--tandem mass spectrometry (HPLC-MS/MS) analysis (Shimadzu Co., Japan) was performed to assess the pharmacokinetic properties of 29 components in QLQX according to the method described in our previous study ([@B64]). Briefly, chromatographic separation was achieved on an Agilent ZOBRAX XDB-C~18~ column (4.6 mm × 50 mm, 3.5 µm) maintained at 40°C. The mobile phase consisted of water (A) and methanol (B) both containing 0.1% (*v/v*) formic acid for astragaloside, calycosin-7-glucoside, sinapine bisulfate, and ginsenoside Rb~1~, Rb~2~, Rg~1~, Rg~3~, Rc, Rd, Re, Rf, and F~2~ detection with a gradient elution. The mobile phase consisted of water (A) and acetonitrile (B) both containing 0.1% (*v/v*) formic acid for salvianolic acid A, salvianolic acid B, danshensu, lithospermic acid, rosmarinic acid, protocatechuic acid, hydroxysafflor yellow A, formononetin, hesperidin, rutin, and quercetin detection with a gradient elution. The mobile phase consisted of water containing 5 mM ammonium acetate (A) and methanol containing 0.1% formic acid (B) for aconitine, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine, and benzoylhypaconine detection with a gradient elution. The flowrate was set at 0.45 ml/min, and the injection volume was 10 µl. The quantitative analysis was performed with multiple reaction monitoring in positive and negative ion modes.

Plasma Sample Preparation {#s2_3}
-------------------------

The powder of QLQX was diluted with 0.5% sodium carboxymethyl cellulose yielding a concentration of 0.13 g/ml suspension. Sprague--Dawley rats were intragastrically administered with QLQX suspension at 1.3 g/kg, and the blood samples were collected into a heparinized centrifuge tube at 5, 10, 20, 40, 60, 90, 120, 180, 240, 360, 480, 720, and 1,440 min after dosing *via* the postorbital venous plexus. Then, the whole blood was centrifuged at 12,000 rpm for 10 min, the supernatant was obtained, and stored at −80°C until analysis. The preparation of blood samples was conducted according to our previous research ([@B64]). This study was carried out in accordance with the principles of the Basel Declaration and recommendations of guidelines of the National Institutes of Health. The protocol was approved by the Ethics Committee of Tianjin University of Traditional Chinese Medicine (Tianjin, China).

Targets Fishing {#s2_4}
---------------

The targets of active components in QLQX determined by pharmacokinetics analysis were obtained from three databases: DrugBank,[^1^](#fn1){ref-type="fn"} Swiss Target Prediction,[^2^](#fn2){ref-type="fn"} and Similarity Ensemble Approach (SEA).[^3^](#fn3){ref-type="fn"} Known therapeutic targets of CHF were collected from the DrugBank database[^1^](#fn1){ref-type="fn"} and DisGeNet database[^4^](#fn4){ref-type="fn"}.The keywords "chronic heart failure" and "congestive heart failure" were used, and the targets were human genes/proteins enrolled in this study.

Network Construction and Topological Analysis {#s2_5}
---------------------------------------------

The C--T network was constructed using Cytoscape (Version 3.2.1) ([@B47]). Four topological features (degree, betweenness centrality, average shortest path length, and closeness centrality) were analyzed using Network Analyzer ([@B1]). The major hub network comprising putative major components and major targets was extracted by defining nodes with degrees higher than the average number of neighbors.

Clustering Analysis {#s2_6}
-------------------

MCODE (Version 1.4.2) ([@B4]) was employed to identify the major hubs of QLQX against CHF. MCODE analyzes the network based on the given parameter, and it assigns the weight to the vertex in local neighborhoods from the dense regions using vertex weighting, cluster prediction, and optimal postprocessing. Finally, we defined the hub targets by considering the results of the topological analysis and clustering analysis. To obtain the proteins interacting with the hub targets, the STRING[^5^](#fn5){ref-type="fn"} database was used, and the association score ≥0.9 was considered the highest confidence.

Pathway Enrichment Analysis {#s2_7}
---------------------------

ClueGO (Version 2.3.2) ([@B44]) was utilized to analyze the representative biological processes and pathways associated with QLQX against CHF. All targets obtained from the C--T network were imported. GO biological process, Reactome pathway, and Wiki pathway were selected from the ClueGO setting panel, and a two-sided hypergeometric test with *p* ≤ 0.01 significance level for biological process analysis and a *p* ≤ 0.05 significance level for pathway analysis was used.

Cell Culture and Treatments {#s2_8}
---------------------------

HCMECs were maintained in complete growth medium (90% H-DMEM, 10% FBS, and penicillin/streptomycin). All cells were cultured at 37°C in a humidified atmosphere containing 5% CO~2~. After three or four passages, the HCMECs were digested with 0.25% trypsin and adjusted to a density of 5 × 10^4^ cells/ml and 1 × 10^5^ cells/ml for cell viability assay and Western blot analysis, respectively. The powder of QLQX was accurately weighed and dissolved in complete growth medium to various concentrations (0.15 and 0.3 mg/ml). The cells used for cell viability assay were seeded on 96-well plates in 100 µl of complete growth medium (0.15 or 0.3 mg/ml QLQX were added) for 24, 48, or 72 h and were then treated with 10 mM Hcy for another 24 h. The cells used for Western blot analysis were divided into the following groups: control, model, positive-captopril (CA), QLQX-low (-L), and QLQX-high (-H). Cells in the control group were cultured without any treatments. In the model group, the HCMECs (1 × 10^5^/ml) were cultured in 3 ml complete growth medium (10 mM Hcy was added) for 24 h. In the CA, -L, and -H groups, cells were pretreated with 0.075 mg/ml captopril, 0.15 mg/ml QLQX, and 0.3 mg/ml QLQX for 48 h, respectively, and then cultured in complete growth medium (10 mM Hcy was added) for a further 24 h.

Cell Viability Assay {#s2_9}
--------------------

Cell viability of the HCMECs was evaluated using the MTT assay. Cells were seeded on 96-well plates with a density of 5 × 10^4^ cells/ml in 100 µl of complete growth medium (0.15 or 0.3 mg/ml QLQX were added) for 24, 48, or 72 h and were then treated with 10 mM Hcy for 24 h. Following treatment, 10 μl of MTT (5 mg/ml) was added to each well. After 4 h, the culture medium was removed, and 100 μl of dimethyl sulfoxide (Beyotime, Shanghai, China) was added. The absorbance was measured at 570 nm using a microplate reader (Infinite M200 Pro, Tecan, Switzerland), and the cell viability was expressed as a percentage of the value of the untreated group.

Western Blot Analysis {#s2_10}
---------------------

HCMECs (1 × 10^5^ cells/ml) were seeded on 60 × 20-mm dishes in 3 ml of complete growth medium for 24 h. After treatment, the HCMECs were scraped off and washed twice with cold phosphate-buffered saline. The cells were solubilized by radioimmunoprecipitation assay lysis buffer (Beyotime, China) containing 1% phenylmethylsulphonyl fluoride (Beyotime, China) and 1% phosphatase inhibitor for 20 min on ice. Whole-cell lysates were clarified by centrifuging at 12,000 rpm for 10 min at 4°C, and the supernatants were collected. Protein concentrations were determined by the BCA protein assay. The protein samples were mixed with sodium dodecyl sulfate polyacrylamide gel electrophoresis sample loading buffer (Beyotime, China) and boiled at 100°C for 5 min. Equal concentrations of protein (2 mg/ml) were separated by electrophoresis on 10% sodium dodecyl sulphate polyacrylamide gels and were transferred onto polyvinylidene difluoride membranes. These membranes were soaked in 5% skimmed milk, and dissolved with TBST buffer (Tris Buffer Saline supplemented with 0.1% Tween-20) 5 times (15 min each time) to block nonspecific binding sites. The membranes were then incubated overnight at 4°C with the primary antibodies (*VEGFA*, *STAT3*, *p-STAT3*, *JAK2*, *p-JAK2*, *IL-6*, *ADRB1*, and *ADRB2*). After washing with TBST, the membranes were incubated for 2 h at room temperature with horseradish peroxidase-labeled secondary antibodies. After rewashing with TBST, the membranes were scanned using a fluorescent scanner (Odyssey CLX, Gene Company Limited, USA). Band intensity was analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Statistical Analysis {#s2_11}
--------------------

Data were presented as mean ± SD and analyzed using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). One-way analysis of variance (ANOVA) was used, and *p*-value \< 0.05 was considered statistically significant.

Results {#s3}
=======

Pharmacokinetics Study of 29 Components in QLQX by HPLC-MS/MS {#s3_1}
-------------------------------------------------------------

Pharmacokinetic properties of 29 components in QLQX (astragaloside, calycosin-7-glucoside, sinapine bisulfate, ginsenoside Rb~1~, Rb~2~, Rg~1~, Rg~3~, Rc, Rd, Re, Rf, F~2~, salvianolic acid A, salvianolic acid B, danshensu, lithospermic acid, rosmarinic acid, protocatechuic acid, hydroxysafflor yellow A, formononetin, hesperidin, rutin, quercetin, aconitine, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine, and benzoylhypaconine) were studied using the HPLC-MS/MS method according to the method in our previous study ([@B64]). The pharmacokinetic properties of 29 components are shown in [**Table 1**](#T1){ref-type="table"}, and the mean concentration--time curves are shown in [**Figure 2**](#f2){ref-type="fig"}. These 29 components of QLQX detected in the blood of the rats and with appropriate pharmacokinetic properties were determined to be the main active components and used to construct the C--T network.

###### 

Pharmacokinetic properties of 29 components in QLQX determined by HPLC-MS/MS.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Compounds                 Polarity   Parent\   Daughter\   Pharmacokinetic parameters                                                  
                                             (m/z)     (m/z)                                                                                   
  ----- ------------------------- ---------- --------- ----------- ---------------------------- ------------- -------------- ----------------- -----------------
  1     Astragaloside             Positive   807.5     627.3       120.46 ± 45.03               0.67 ± 0.00   5.74 ± 0.78    320.92 ± 79.10    369.14 ± 103.83

  2     Calycosin-7-glucoside     Positive   447.2     285.2       31.49 ± 12.00                0.67 ± 0.06   6.05 ± 3.34    103.26 ± 47.63    120.71 ± 50.71

  3     Sinapine bisulfate        Positive   310.2     251.2       1.35 ± 0.62                  1.50 ± 0.00   3.52 ± 0.17    3.98 ± 1.21       8.76 ± 2.85

  4     Ginsenoside Rb~1~         Positive   1,131.7   365.2       323.00 ± 91.00               0.67 ± 0.00   9.16 ± 3.18    590.15 ± 257.83   713.49 ± 270.66

  5     Ginsenoside Rb~2~         Positive   1,107.8   335.0       31.25 ± 9.89                 1.50 ± 0.06   10.11 ± 4.53   143.73 ± 35.67    307.99 ± 79.92

  6     Ginsenoside Rg~1~         Positive   823.5     643.5       113.44 ± 48.22               0.67 ± 0.00   8.69 ± 3.17    362.17 ± 118.25   422.31 ± 180.63

  7     Ginsenoside Rg~3~         Positive   807.6     364.9       20.49 ± 7.16                 0.67 ± 0.24   5.03 ± 2.02    67.13 ± 27.93     89.81 ± 34.43

  8     Ginsenoside Rc            Positive   1,101.6   789.5       180.00 ± 70.00               0.67 ± 0.00   4.32 ± 2.10    432.71 ± 178.66   493.04 ± 233.70

  9     Ginsenoside Rd            Positive   969.5     789.6       97.49 ± 31.00                0.67 ± 0.00   5.90 ± 1.14    204.66 ± 87.30    257.92 ± 101.52

  10    Ginsenoside Re            Positive   969.6     789.6       118.94 ± 52.82               0.67 ± 0.06   7.33 ± 3.45    268.84 ± 103.24   310.95 ± 147.36

  11    Ginsenoside Rf            Positive   823.5     365.2       43.03 ± 12.49                0.67 ± 0.00   6.12 ± 3.53    130.27 ± 27.91    177.68 ± 68.95

  12    Ginsenoside F~2~          Positive   807.5     627.7       3.83 ± 1.23                  0.67 ± 0.00   6.23 ± 2.89    12.73 ± 3.62      18.64 ± 5.28

  13    Salvianolic acid A        Negative   493.1     294.9       8.96 ± 2.90                  0.17 ± 0.00   7.50 ± 4.92    18.59 ± 7.91      21.40 ± 7.36

  14    Salvianolic acid B        Negative   717.3     519.2       502.00 ± 68.43               0.33 ± 0.14   5.32 ± 1.32    818.47 ± 249.00   980.47 ± 112.07

  15    Danshensu                 Negative   196.9     134.8       98.60 ± 23.66                0.67 ± 0.00   3.52 ± 0.42    290.92 ± 68.38    390.90 ± 66.50

  16    Lithospermic acid         Negative   537.4     493.2       77.25 ± 19.90                0.67 ± 0.00   4.80 ± 0.89    173.49 ± 38.57    216.94 ± 27.39

  17    Rosmarinic acid           Negative   358.9     160.9       52.16 ± 5.96                 0.67 ± 0.00   5.28 ± 1.35    78.65 ± 35.72     96.69 ± 24.81

  18    Protocatechuic acid       Negative   152.9     108.8       17.00 ± 7.26                 0.67 ± 0.00   8.38 ± 1.02    44.15 ± 18.02     61.03 ± 10.51

  19    Hydroxysafflor yellow A   Negative   611.2     491.0       8.62 ± 3.51                  0.17 ± 0.00   5.03 ± 2.00    15.63 ± 4.42      21.99 ± 6.25

  20    Formononetin              Negative   266.9     251.7       5.17 ± 1.13                  0.17 ± 0.00   5.07 ± 2.13    14.70 ± 5.48      18.04 ± 6.69

  21    Hesperidin                Negative   609.2     300.9       64.63 ± 23.49                0.67 ± 0.00   3.34 ± 0.42    154.32 ± 66.50    187.77 ± 34.98

  22    Rutin                     Negative   609.2     299.6       3.63 ± 1.25                  0.33 ± 0.00   5.33 ± 1.27    12.29 ± 2.47      16.92 ± 5.21

  23    Quercetin                 Negative   301.1     150.7       3.23 ± 1.26                  0.67 ± 0.00   5.04 ± 0.98    10.96 ± 3.42      15.03 ± 5.28

  24    Aconitine                 Positive   646.4     586.4       1.44 ± 0.68                  0.33 ± 0.00   18.35 ± 5.44   7.03 ± 2.31       18.16 ± 6.87

  25    Mesaconitine              Positive   632.3     572.3       0.52 ± 0.16                  0.17 ± 0.06   6.23 ± 1.23    3.95 ± 1.02       5.13 ± 2.32

  26    Hypaconitine              Positive   616.3     556.3       1.97 ± 0.33                  0.33 ± 0.00   8.01 ± 2.39    7.89 ± 2.57       13.85 ± 6.67

  27    Benzoylaconine            Positive   604.2     554.3       1.83 ± 0.33                  1.00 ± 0.00   18.63 ± 7.20   8.63 ± 2.39       25.94 ± 9.03

  28    Benzoylmesaconine         Positive   590.2     540.3       5.84 ± 0.61                  0.67 ± 0.11   8.23 ± 2.02    20.13 ± 6.27      35.34 ± 11.22

  29    Benzoylhypaconine         Positive   574.2     542.3       0.67 ± 0.32                  0.67 ± 0.00   12.88 ± 3.47   4.03 ± 1.03       7.80 ± 3.84
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

![Mean concentration-time profiles of astragaloside (QLQX-1), calycosin-7-glucoside (QLQX-2), sinapine bisulfate (QLQX-3), ginsenoside Rb~1~ (QLQX-4), Rb~2~ (QLQX-5), Rg~1~ (QLQX-6), Rg~3~ (QLQX-7), Rc (QLQX-8), Rd (QLQX-9), Re (QLQX-10), Rf (QLQX-11), F~2~ (QLQX-12), salvianolic acid A (QLQX-13), salvianolic acid B (QLQX-14), danshensu (QLQX-15), lithospermic acid (QLQX-16), rosmarinic acid (QLQX-17), protocatechuic acid (QLQX-18), hydroxysafflor yellow A (QLQX-19), formononetin (QLQX-20), hesperidin (QLQX-21), rutin (QLQX-22), quercetin (QLQX-23), aconitine (QLQX-24), mesaconitine (QLQX-25), hypaconitine (QLQX-26), benzoylaconine (QLQX-27), benzoylmesaconine (QLQX-28), benzoylhypaconine (QLQX-29).](fphar-10-01046-g002){#f2}

Compound--Target Network Construction {#s3_2}
-------------------------------------

Totally, 1,288 targets were found for the 29 components using Drugbank, Swiss Target Prediction, and SEA databases. The detailed target information for the 29 components in QLQX is shown in [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}. A total of 812 candidate targets of CHF were obtained from DisGeNet and Drugbank databases after removing redundant entries ([**Supplementary Table S2**](#SM2){ref-type="supplementary-material"}). Taking the intersection of the 1,288 putative targets of the 29 components in QLQX and the 812 candidate targets associated with CHF, a total of 120 consensus targets were collected as potential therapeutic targets of QLQX against CHF and used to establish the C--T network. As a result, a C--T network comprising 29 components and 120 consensus targets was constructed using Cytoscape. As shown in [**Figure 3A**](#f3){ref-type="fig"}, the network comprised 149 nodes (29 components and 120 targets) and 446 edges.

![The networks associating with QLQX in the treatment of CHF. **(A)** The component-target network consisted of 149 nodes and 446 edges. **(B)** The major hub network define by nodes with degree higher the average number of neighbors (5.830). **(C)** The PPI network of hub targets obtained from STRING database and constructed by Cytoscape. The ellipse nodes represent targets, and the diamond nodes represent active components in QLQX, the widths of the edges represent the order of the edge betweenness and the colors of the nodes are illustrated from red to yellow in descending order of degree values.](fphar-10-01046-g003){#f3}

Network Topological Analysis {#s3_3}
----------------------------

Network analyzer was used to calculate four topological features (degree, betweenness centrality, average shortest path length, and closeness centrality) of the nodes of the C--T network. Nodes with degrees higher than the average number of neighbors (5.830) were identified and extracted as the major hub networks ([**Figure 3B**](#f3){ref-type="fig"}). Among these, 32 major targets with higher degree, closeness centrality, betweenness centrality, and lower average shortest path length were recognized as the major putative targets, and the results are shown in [**Table 2**](#T2){ref-type="table"}. Twenty-eight components were identified as the main active components ([**Table 3**](#T3){ref-type="table"}), and quercetin had the highest degree and betweenness centrality of 46 and 0.35, respectively, thereby indicating that quercetin has the most important position in the network.

###### 

The topological parameters of 32 major targets.

  Swiss prot   Genes/proteins   Description                                                      Degree   Betweenness centrality   Average shortest path length   Closeness centrality
  ------------ ---------------- ---------------------------------------------------------------- -------- ------------------------ ------------------------------ ----------------------
  Q9Y6L6       SLCO1B1          Solute carrier organic anion transporter family member 1B1       12       0.09496758               2.69078947                     0.37163814
  Q9NPD5       SLCO1B3          Solute carrier organic anion transporter family member 1B3       11       0.04862563               3.28289474                     0.30460922
  P43166       CA7              Carbonic anhydrase 7                                             11       0.04690937               2.40131579                     0.41643836
  P22748       CA4              Carbonic anhydrase 4                                             11       0.04164377               2.45394737                     0.4075067
  P15692       VEGFA            Vascular endothelial growth factor A                             11       0.11260667               2.79605263                     0.35764706
  Q8TCC7       SLC22A8          Solute carrier family 22 member 8                                10       0.03755913               3.23026316                     0.3095723
  P15121       AKR1B1           Aldo-keto reductase family 1 member B                            10       0.02861805               2.70394737                     0.36982968
  P08183       ABCB1            Multidrug resistance protein 1                                   10       0.06692038               2.67763158                     0.37346437
  Q14765       STAT4            Signal transducer and activator of transcription 4               9        4.74E−04                 4.08552632                     0.24476651
  P46721       SLCO1A2          Solute carrier organic anion transporter family member 1A2       9        4.74E−04                 4.08552632                     0.24476651
  P40763       STAT3            Signal transducer and activator of transcription 3               9        4.74E−04                 4.08552632                     0.24476651
  P20813       CYP2B6           Cytochrome P450 2B6                                              9        4.74E−04                 4.08552632                     0.24476651
  P10632       CYP2C8           Cytochrome P450 2C8                                              9        0.05421697               2.75657895                     0.3627685
  P05023       ATP1A1           Sodium/potassium-transporting ATPase subunit alpha-1             9        4.74E−04                 4.08552632                     0.24476651
  P04798       CYP1A1           Cytochrome P450 1A1                                              9        4.74E−04                 4.08552632                     0.24476651
  P02766       TTR              Transthyretin                                                    9        0.02882135               2.53289474                     0.39480519
  P08684       CYP3A4           Cytochrome P450 3A4                                              8        0.01906502               3.15131579                     0.31732777
  P07550       ADRB2            Beta-2 adrenergic receptor                                       8        0.04366511               3.20394737                     0.31211499
  P07451       CA3              Carbonic anhydrase 3                                             8        0.03416389               2.45394737                     0.4075067
  Q9UNQ0       ABCG2            ATP binding cassette subfamily G member 2 (Junior blood group)   7        0.0203742                2.74342105                     0.36450839
  Q9ULX7       CA14             Carbonic anhydrase 14                                            7        0.02057174               2.625                          0.38095238
  P31645       SLC6A4           Solute carrier family 6 member 4                                 7        0.0021531                3.83552632                     0.26072041
  P23975       SLC6A2           Solute carrier family 6 member 2                                 7        0.0021531                3.83552632                     0.26072041
  O43570       CA12             Carbonic anhydrase 12                                            7        0.01886671               2.66447368                     0.37530864
  Q14524       SCN5A            Sodium voltage-gated channel alpha subunit 5                     6        1.51E−04                 4.09868421                     0.24398074
  P24462       CYP3A7           Cytochrome P450 3A7                                              6        1.51E−04                 4.09868421                     0.24398074
  P20815       CYP3A5           Cytochrome P450 3A5                                              6        1.51E−04                 4.09868421                     0.24398074
  P10635       CYP2D6           Cytochrome P450 2D6                                              6        1.51E−04                 4.09868421                     0.24398074
  P08588       ADRB1            Adrenoceptor beta 1                                              6        1.51E−04                 4.09868421                     0.24398074
  P08254       MMP3             Matrix metallopeptidase 3                                        6        0.00514916               2.95394737                     0.33853007
  P00918       CA2              Carbonic anhydrase 2                                             6        0.01628126               2.67763158                     0.37346437
  O15244       SLC22A2          Solute carrier family 22 member 2                                6        1.51E−04                 4.09868421                     0.24398074

###### 

The topological parameters of 28 main active components.

  No.       Compounds                 Degree   Betweenness centrality   Average shortest path length   Closeness centrality
  --------- ------------------------- -------- ------------------------ ------------------------------ ----------------------
  QLQX-23   Quercetin                 46       0.34943416               2.21052632                     0.45238095
  QLQX-20   Formononetin              37       0.20139204               2.47368421                     0.40425532
  QLQX-15   Danshensu                 27       0.14738861               2.85526316                     0.35023041
  QLQX-18   Protocatechuic acid       25       0.14911094               2.65789474                     0.37623762
  QLQX-21   Hesperidin                22       0.10590127               2.71052632                     0.36893204
  QLQX-3    Sinapine bisulfate        18       0.06332468               2.94736842                     0.33928571
  QLQX-17   Rosmarinic acid           18       0.05489072               2.96052632                     0.33777778
  QLQX-22   Rutin                     15       0.03964651               2.98684211                     0.33480176
  QLQX-1    Astragaloside             15       0.13507408               3.44736842                     0.29007634
  QLQX-29   Benzoylhypaconine         15       0.02499921               3.17105263                     0.3153527
  QLQX-27   Benzoylaconine            14       0.0210363                3.18421053                     0.31404959
  QLQX-26   Hypaconitine              14       0.0210363                3.18421053                     0.31404959
  QLQX-7    Ginsenoside Rg~3~         13       0.03221083               3.19736842                     0.3127572
  QLQX-13   Salvianolic acid A        13       0.0102585                3.19736842                     0.3127572
  QLQX-28   Benzoylmesaconine         13       0.01850138               3.19736842                     0.3127572
  QLQX-25   Mesaconitine              13       0.01786266               3.19736842                     0.3127572
  QLQX-24   Aconitine                 13       0.01786266               3.19736842                     0.3127572
  QLQX-16   Lithospermic acid         12       0.00961587               3.21052632                     0.31147541
  QLQX-8    Ginsenoside Rc            11       0.01141274               3.22368421                     0.31020408
  QLQX-4    Ginsenoside Rb~1~         11       0.01141274               3.22368421                     0.31020408
  QLQX-9    Ginsenoside Rd            10       0.0092025                3.23684211                     0.30894309
  QLQX-6    Ginsenoside Rg~1~         10       0.0092025                3.23684211                     0.30894309
  QLQX-5    Ginsenoside Rb~2~         10       0.0092025                3.23684211                     0.30894309
  QLQX-12   Ginsenoside F~2~          10       0.0092025                3.23684211                     0.30894309
  QLQX-11   Ginsenoside Rf            10       0.0092025                3.23684211                     0.30894309
  QLQX-10   Ginsenoside Re            10       0.0092025                3.23684211                     0.30894309
  QLQX-14   Salvianolic acid b        9        0.0045723                3.25                           0.30769231
  QLQX-19   Hydroxysafflor yellow a   7        0.01639755               3.09210526                     0.32340426

Clustering Analysis {#s3_4}
-------------------

MCODE was used to identify the major hubs of QLQX against CHF, which generated a well-organized cluster containing 17 nodes (*SLC22A8*, *SLCO1B3*, QLQX-9, QLQX-11, QLQX-5, QLQX-8, *CYP1A1*, QLQX-12, QLQX-6, *ATP1A1*, *VEGFA*, *CYP2B6*, *STAT3*, *SLCO1A2*, QLQX-10, QLQX-4, and *STAT4*). Taking the intersection of the topological analysis and clustering analysis results, a total of nine consensus targets were collected to be hub targets of QLQX against CHF, namely, *SLC22A8*, *SLCO1B3*, *CYP1A1*, *ATP1A1*, *VEGFA*, *CYP2B6*, *STAT3*, *SLCO1A2*, and *STAT4*. Then, the nine consensus targets were used as hub targets and submitted to STRING to generate the proteins interacting with these hub targets. The STRING database provides both experimental and predicted interaction information and provides a probabilistic association confidence score by calculation. As shown in [**Table 4**](#T4){ref-type="table"}, six target genes, namely, *VEGFA*, *CYP1A1*, *CYP2B6*, *ATP1A1*, *STAT3*, and *STAT4*, and 10 predicted functional genes, namely, *KDR*, *FLT1*, *NRP2*, *JAK2*, *EGFR*, *IL-6*, *AHR*, *ATP1B1*, *JAK1*, and *HIF1A*, having the highest confidence with an association score ≥0.9 were imported into Cytoscape 3.2.1 ([**Figure 3C**](#f3){ref-type="fig"}). The network analysis tool was used to analyze the PPI network and targets with a higher degree played an important role in central correlation. The results are shown in [**Table 5**](#T5){ref-type="table"}.

###### 

The proteins interacting of hub targets.

  Node 1   Interaction   Node 2   Score
  -------- ------------- -------- -------
  VEGFA    pp            KDR      0.999
  VEGFA    pp            FLT1     0.999
  VEGFA    pp            NRP2     0.998
  JAK2     pp            STAT3    0.998
  EGFR     pp            STAT3    0.998
  CYP1A1   pp            AHR      0.997
  JAK1     pp            STAT3    0.997
  ATP1A1   pp            ATP1B1   0.997
  IL6      pp            STAT3    0.997
  VEGFA    pp            HIF1A    0.996
  VEGFA    pp            STAT3    0.994
  NRP2     pp            FLT1     0.988
  FLT1     pp            KDR      0.988
  HIF1A    pp            STAT3    0.986
  STAT4    pp            JAK2     0.984
  NRP2     pp            KDR      0.983
  STAT4    pp            JAK1     0.983
  VEGFA    pp            EGFR     0.979
  IL6      pp            JAK2     0.975
  HIF1A    pp            EGFR     0.973
  IL6      pp            JAK1     0.968
  JAK1     pp            EGFR     0.966
  VEGFA    pp            IL6      0.959
  JAK2     pp            JAK1     0.943
  STAT4    pp            STAT3    0.938
  JAK2     pp            EGFR     0.928
  CYP1A1   pp            CYP2B6   0.928
  IL6      pp            EGFR     0.921

###### 

The topological parameters of PPI network.

  Genes/proteins   Degree   Betweenness centrality   Average shortest path length   Closeness centrality
  ---------------- -------- ------------------------ ------------------------------ ----------------------
  VEGFA            7        0.47407407               1.3                            0.76923077
  STAT3            7        0.21481481               1.3                            0.76923077
  EGFR             6        0.08888889               1.4                            0.71428571
  JAK2             5        0.01481481               1.8                            0.55555556
  JAK1             5        0.01481481               1.8                            0.55555556
  IL6              5        0.05925926               1.5                            0.66666667
  KDR              3        0                        2                              0.5
  FLT1             3        0                        2                              0.5
  NRP2             3        0                        2                              0.5
  HIF1A            3        0                        1.7                            0.58823529
  STAT4            3        0                        2                              0.5
  CYP1A1           2        1                        1                              1
  AHR              1        0                        1.5                            0.66666667
  ATP1A1           1        0                        1                              1
  ATP1B1           1        0                        1                              1
  CYP2B6           1        0                        1.5                            0.66666667

Pathway Enrichment Analysis {#s3_5}
---------------------------

To analyze the representative biological processes and pathways associated with the 120 targets of the C--T network, GO biological, Reactome, and Wiki pathway analysis were used to explore the potential biological processes and pathways affected by QLQX through analysis of the 120 targets. The biological processes were ranked by their nominal *P* values with a cutoff at 0.01, and 120 targets were enriched to 26 biological processes; the top 10 are shown in [**Supplementary Table S3**](#SM3){ref-type="supplementary-material"} and [**Figure 4A**](#f4){ref-type="fig"}. The pathways were ranked by their nominal *p* values with a cutoff at 0.05, and the top 10 pathways included interleukin-4 and 13 signaling, phase I functionalization of compounds, drug induction of bile acid pathway, xenobiotics, tamoxifen metabolism, reversible hydration of carbon dioxide, electron transport chain, adrenoceptors, adenosine P1 receptors, and angiotensin-converting enzyme inhibitor pathway ([**Figure 4B**](#f4){ref-type="fig"}). The functional targets involved in each pathway are illustrated in [**Supplementary Table S4**](#SM4){ref-type="supplementary-material"}. The C--T pathway/biological process network (C--T--P) was constructed using Cytoscape ([**Figure 5**](#f5){ref-type="fig"}) based on the interactions among the 29 components, 120 consensus targets, and top 10 biological processes and pathways.

![ClueGO analysis of the candidate targets. **(A)** Representative biological process among 120 candidate targets. **(B)** Representative reactome and Wiki pathway analysis amng 120 candidate targets. Only top ten concerned biological processes and pathways were shown in figures.](fphar-10-01046-g004){#f4}

![The component-target-pathway/biological process network. The red diamond nodes represent the 29 active components in QLQX, the yellow ellipse nodes represent 120 putative targets associated with QLQX in the treatment of CHF, the wathet V nodes represent top ten biological processes and the mazarine triangle nodes represent top ten pathways related the 20 putative.](fphar-10-01046-g005){#f5}

Experimental Validation of Key Targets and Pathway {#s3_6}
--------------------------------------------------

MTT assays showed that 0.15 (-L) and 0.3 mg/ml (-H) QLQX dramatically inhibited Hcy-induced injury in the HCMEC at 48 and 72 h in a time-dependent manner ([**Figure 6**](#f6){ref-type="fig"}). To determine the mechanisms of QLQX in the treatment of CHF, some of the key proteins with a higher degree in the PPI network were experimentally validated in the HCMEC. Besides, considering that *ADRB1* and *ADRB2* play an essential role in heart failure ([@B11]; [@B48]), *ADRB1* and *ADRB2* were used as a control to validate the effect of QLQX. As shown in [**Figure 6**](#f6){ref-type="fig"}, QLQX significantly increased the ratio between *ADRB1* and *ADRB2*. Meanwhile, QLQX significantly increased the expression level of *VEGFA* and inhibited the expression levels of *p-STAT3*, *p-JAK2*, and *IL-6* in a dose-dependent manner.

![Experimental validation of key targets and pathway in HCMEC. **(A)** Effect of QLQX treatment on Hcy-induced HCMEC cell viability. HCMECs were treated with 0.15 mg/mL and 0.3 mg/mL QLQX for 24, 48, and 72 h, after then cells were treated with Hcy for 24 h. The cell viability was determined using the MTT assay. **(B)** Effect of QLQX treatment on Hcy-induced *ADRB1/Anti-ADRB2* ratio in HCMEC. **(C)** Effect of QLQX and captopril treatment on Hcy-induced *VEGFA* expression in HCMEC. **(D)** Effect of QLQX and captopril treatment on Hcy-induced *IL-6* expression in HCMEC. **(E)** Effect of QLQX and captopril treatment on Hcy-induced phosphorylation of STAT3/JAK2 signaling pathway. HCMECs were treated with 0.075 mg/mL, 0.3 mg/mL QLQX for 48 h and exposed to 10 mM Hcy for a further 24 h. The levels of *VEGFA, IL-6, p-STAT3*, and *p-JAK2* expression were determined by western blot. Data were presented as mean SD of three independent experiments. \**p* \< 0.05 or \*\**p* \< 0.01 compared with the Hcy-untreated control. ^\#^ *p* \< 0.05 or ^\#\#^ *p* \< 0.01 compared with the Hcy-treated control.](fphar-10-01046-g006){#f6}

Discussion {#s4}
==========

As a multicomponent drug, QLQX has been used for several years to treat CHF in China and has been demonstrated as effective in lowering the NT-proBNP level in CHF patients ([@B31]). However, its "multicompound, multitarget" characteristics make it difficult to decipher the active ingredients and mechanisms of QLQX in the treatment against CHF.

Integrated strategies based on network pharmacology provide a useful approach to investigate the active components and molecular mechanisms. For instance, [@B16] proposed a "main active compound-based network pharmacology" based on quantitative analysis of components to explore the anticancer mechanism of CKI. They selected herbs used in the clinical therapy of hepatoma to ascertain molecular targets and antitumor mechanisms, emphasizing the combination of clinical study and network pharmacology. However, in previous studies, all herbal ingredients were collected from herb databases and filtered according to absorption, distribution, metabolism, and excretion properties or drug-likeness value, which may be inconsistent with the ingredients present in the blood ([@B17]). Here, we proposed an integrated strategy *via* pharmacokinetics study, network analysis, and experimental validation to achieve an accurate and systematic exploration of the mechanisms of QLQX against CHF.

In this study, the 29 components of QLQX showing proper pharmacokinetics behavior in rats were determined to be the active ingredients of QLQX. These compounds were mainly categorized as triterpenoid saponins, phenolic acids, flavonoids, and alkaloids. Particularly, astragaloside, ginsenoside Rb~1~, Rb~2~, Rg~1~, Rg~3~, Rc, Rd, Re, Rf, and ginsenoside F~2~, as triterpenoid saponins, are known for their anti-inflammatory property during the period of ventricular remodeling ([@B49]; [@B43]); salvianolic acid A, salvianolic acid B, danshensu, lithospermic acid, rosmarinic acid, and protocatechuic acid, as phenolic acids, exert cardioprotection through promoting angiogenesis in animal models ([@B61]); calycosin-7-glucoside, hydroxysafflor yellow A, formononetin, hesperidin, rutin, and quercetin, as flavonoids, can reduce cardiomyocytes damage and apoptosis and improve cardiac function by decreasing oxidative stress ([@B34]); and aconitine, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine, benzoylhypaconine, and sinapine bisulfate, as alkaloids, can improve left ventricular systolic and diastolic function ([@B33]). Moreover, the hub targets of these active ingredients were determined *via* combining network topological parameters with clustering and PPI network analysis. In total, 6 targets, namely, *VEGFA*, *CYP1A1*, *CYP2B6*, *ATP1A1*, *STAT3*, and *STAT4*, and 10 predicted functional targets, namely, *KDR*, *FLT1*, *NRP2*, *JAK2*, *EGFR*, *IL-6*, *AHR*, *ATP1B1*, *JAK1*, and *HIF1A* were collected as hub targets of QLQX against CHF.

As the leading cause of cardiovascular mortality, CHF is associated with many pathogenic factors, such as increased hemodynamic overload, ventricular remodeling, neurohormonal activation, and energy metabolism disorder ([@B18]; [@B52]). In recent years, increasing evidence has shown that cardiac microvascular and microcirculation functions are closely related, in that, proper cardiac function requires myocardial oxygen balance. Furthermore, the perturbations in microcirculation caused by the interplay of neurohumoral, metabolic, and endothelium-derived factors lead to cardiac microvascular dysfunction and further result in cardiac insufficiency or heart failure ([@B9]; [@B22]).

It is thought that the presence of endothelial dysfunction, which induced by impairment of endothelium-dependent relaxation of blood vessels, might contributed to the pathogenesis of heart failure ([@B27]). Previous study have suggested that Hcy could initiate mitochondrial dysfunction, which contributes to the cell apoptosis and chronic inflammation, thereby resulting in endothelial dysfunction ([@B21]; [@B69]). In this manuscript, the Hcy-induced HCMECs injury was used as the model to explore the role of QLQX in endothelial dysfunction of damaged microvascular endothelial cell. It has been shown that, captopril, as a positive control drug to treat HCMEC in our study, improves endothelium-dependent vasodilatation in patients with CHF ([@B12]). Meanwhile, captopril can increase vascular endothelial growth factor (VEGFA) expression during the period of pathological angiogenesis and rarefaction and inhibit proinflammatory cytokine expression (IL-1β, IL-6, and IL-8) in cultured human coronary artery endothelial cells ([@B19]; [@B20]). Studies have also reported that captopril exerted a cardioprotective effect on heart failure by inhibiting phosphorylation of JAK2/STAT3 ([@B68]).

We have shown that QLQX dramatically inhibited Hcy-induced injury on the HCMEC in a time-dependent manner as observed through MTT assays. Western blotting confirmed that QLQX significantly increased the ratio between *ADRB1* and *ADRB2*, upregulated the expression level of *VEGFA*, and downregulated the expression levels of *p-STAT3*, *p-JAK2*, and *IL-6* in Hcy-induced HCMEC. Evidence has shown that a reduction in the *ADRB1/ADRB2* ratio has been observed in heart failure, and the use of adrenoceptor beta blockers is a cornerstone of current heart failure therapy ([@B5]; [@B58]). Consistent with prior study, we validated the effect of QLQX on the expression of adrenoceptor beta, which showed the prediction power in network pharmacological analysis of our study. On this basis, CHF is defined by cardiac dysfunction associated with ventricular remodeling, and, more recently, an imbalance between angiogenesis and cardiac hypertrophy has increasingly been acknowledged as an additional contributing mechanism ([@B51]). Accordingly, the therapeutic effect of myocardial angiogenesis is emerging as a promising approach for the prevention and treatment of CHF ([@B56]; [@B40]). VEGFA, a cornerstone cytokine of angiogenesis, participates in the process of vascular remodeling and myocardial angiogenesis in CHF through maintenance and repair of luminal endothelium ([@B37]). Besides, increased expression of VEGFA levels has been associated with the process of angiogenesis, and it may be adopted as an indicator of revascularization ([@B28]; [@B57]; [@B60]).

As shown in the present study, QLQX exerts a protective effect against IL-6 secretion induced by Hcy in the HCMEC, which may be associated with negative regulation of the Janus kinase signal transducer and signal transduction activator of transcription (JAK-STAT) signaling. Recent evidence has revealed that inflammation is a critical pathological process of CHF ([@B10]; [@B2]; [@B8]) and high levels of IL-6, a proinflammatory cytokine, have been reported to be an important mediator in chronic inflammatory and cardiovascular disorders ([@B46]; [@B3]). Moreover, IL-6 exerts its action through a specific IL-6R and a soluble IL-6 receptor, whereby the IL-6/IL-6R complex binds to the membrane glycoprotein 130 to induce intracellular signaling pathways ([@B23]; [@B42]). The JAK-STAT pathway is a characteristic signal transduction pathway that plays a crucial role in this process ([@B36]). Specifically, the activated JAK2, a key member of the Janus family of kinases, leads to phosphorylation and activation of a group of transcription factors collectively called STATs. Among them, STAT3 also appears to be involved in a broad range of cytoprotection activities, such as inflammation, angiogenesis, extracellular matrix composition, and apoptosis in the heart ([@B45]). Previous study has implicated astragaloside could improve vascular endothelial dysfunction induced by hyperglycemia by increasing eNOS expression and decreasing the content of IL-6 ([@B29]). Evidence provided by [@B26] showed calycosin protected vascular endothelial from LPS-induced endothelial injury through suppression of ROS and VEGFA level. Furthermore, it has been reported that salvianolic acid A inhibited endothelial dysfunction and vascular remodeling in spontaneously hypertensive rats ([@B54]). All these mentioned above suggest that some compounds in QLQX exerts a protective effect on vascular endothelial, which in another way could support the results in our study.

Therefore, we focused on the inflammation in the HCMEC, as we were interested in the role of the JAK/STAT signaling in the pathogenesis of QLQX against CHF. Inflammatory processes and angiogenesis may be interrelated during the process of CHF, and the angiogenesis factor promotes angiogenesis mainly through signaling pathways, of which JAK2-STAT3 is one of the important ones ([@B14]). It was reported that inflammation and neovascularization in atheromatous plaques might be mediated by VEGFA ([@B38]), and the antihuman IL-6 receptor monoclonal antibody was shown to improve endothelial function in patients with acute coronary syndromes ([@B24]). Thus, QLQX can rectify the injury of microvascular endothelial cells induced by Hcy while significantly decreasing the levels of *IL-6*, *p-JAK2*, and *p-STAT3*, which suggests that QLQX may inhibit inflammatory processes and promote angiogenesis in CHF *via* the JAK/STAT signaling pathway.

Conclusion {#s5}
==========

In the current study, an integrated strategy was used to illustrate the active ingredients and molecular mechanisms of QLQX in the treatment of CHF by adopting pharmacokinetics study, network pharmacological analysis, and experimental validation. In total, 29 ingredients determined by pharmacokinetics study, instead of herb databases, were used for network pharmacology analysis. Through experimental validation of the hub targets (*VEGFA*, *IL-6*, *p-STAT3*, and *p-JAK2*), the JAK/STAT signaling pathway was identified as the mechanism of QLQX against inflammatory process in CHF. Additionally, the established C--T--P network remained a characteristic of multilink and multilevel comprehensive effects of QLQX. These results provided an efficient way to understand the pharmacological mechanisms of traditional Chinese medicine prescriptions.
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